CN105218660B - 重组内皮抑素的新型纯化复性方法及其抗肿瘤应用 - Google Patents
重组内皮抑素的新型纯化复性方法及其抗肿瘤应用 Download PDFInfo
- Publication number
- CN105218660B CN105218660B CN201410315038.8A CN201410315038A CN105218660B CN 105218660 B CN105218660 B CN 105218660B CN 201410315038 A CN201410315038 A CN 201410315038A CN 105218660 B CN105218660 B CN 105218660B
- Authority
- CN
- China
- Prior art keywords
- dialyzate
- rhed
- urea
- sodium acetate
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000000746 purification Methods 0.000 title claims abstract description 35
- 238000004153 renaturation Methods 0.000 title abstract description 53
- 108010079505 Endostatins Proteins 0.000 title abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 7
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 title abstract 2
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 34
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 40
- 239000004202 carbamide Substances 0.000 claims description 29
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 28
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 24
- 239000001632 sodium acetate Substances 0.000 claims description 24
- 235000017281 sodium acetate Nutrition 0.000 claims description 24
- 239000004471 Glycine Substances 0.000 claims description 20
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 15
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 15
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 13
- 238000000502 dialysis Methods 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 7
- 238000005063 solubilization Methods 0.000 claims description 7
- 230000007928 solubilization Effects 0.000 claims description 7
- 238000004925 denaturation Methods 0.000 claims description 6
- 230000036425 denaturation Effects 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 2
- 239000000893 inhibin Substances 0.000 claims 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 230000000857 drug effect Effects 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 41
- 239000000243 solution Substances 0.000 description 26
- 239000003814 drug Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 13
- 238000002512 chemotherapy Methods 0.000 description 13
- 241000699660 Mus musculus Species 0.000 description 12
- 238000011580 nude mouse model Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- 229960004249 sodium acetate Drugs 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- 229960004397 cyclophosphamide Drugs 0.000 description 8
- 229910052697 platinum Inorganic materials 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009465 prokaryotic expression Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000005909 tumor killing Effects 0.000 description 5
- 102400001047 Endostatin Human genes 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 108700008165 endostar Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 101150090473 phb-2 gene Proteins 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- XXCIDEQIWQKILU-UHFFFAOYSA-M sodium;urea;acetate Chemical compound [Na+].CC([O-])=O.NC(N)=O XXCIDEQIWQKILU-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000000998 shell membrane Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- -1 urine Element Chemical compound 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
组别 | 处理因素 | 剂量mg/kg/d | 给药方案 |
1 | 0.9%NaCl | - | sc×15bid |
2 | rhED | 5 | sc×15bid |
3 | rhED | 10 | sc×15bid |
4 | rhED | 15 | sc×15bid |
5 | DDP+rhED | 3(DDP),5(rhED) | ip×7qod+sc×15bid |
6 | DDP+rhED | 3(DDP),10(rhED) | ip×7qod+sc×15bid |
7 | DDP+rhED | 3(DDP),15(rhED) | ip×7qod+sc×15bid |
8 | Endostar | 5 | sc×15bid |
9 | DDP | 3 | ip×7qod |
组别 | 处理因素 | 剂量mg/kg/d | 给药方案 |
1 | 0.9%NaCl | - | iv×15bid |
2 | rhED | 2.5 | iv×15bid |
3 | rhED | 5 | iv×15bid |
4 | rhED | 10 | iv×15bid |
5 | CTX+rhED | 15(CTX),5(rhED) | ip×7qod+iv×15bid |
6 | CTX rhED | 15(CTX),10(rhED) | ip×7qod+iv×15bid |
7 | CTX+rhED | 15(CTX),15(rhED) | ip×7qod+iv×15bid |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410315038.8A CN105218660B (zh) | 2014-07-03 | 2014-07-03 | 重组内皮抑素的新型纯化复性方法及其抗肿瘤应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410315038.8A CN105218660B (zh) | 2014-07-03 | 2014-07-03 | 重组内皮抑素的新型纯化复性方法及其抗肿瘤应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105218660A CN105218660A (zh) | 2016-01-06 |
CN105218660B true CN105218660B (zh) | 2019-02-12 |
Family
ID=54987988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410315038.8A Active CN105218660B (zh) | 2014-07-03 | 2014-07-03 | 重组内皮抑素的新型纯化复性方法及其抗肿瘤应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105218660B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107537027A (zh) * | 2016-06-23 | 2018-01-05 | 南开大学 | Tnfsf15蛋白在制备治疗黑色素瘤药物中的用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058498A1 (en) * | 1999-03-30 | 2000-10-05 | Merck & Co., Inc. | Soluble recombinant endostatin |
WO2001060839A2 (en) * | 2000-02-18 | 2001-08-23 | The United States Of America, As Represented By Secretary Of The Department Of Health And Human Services | Method for refolding recombinant endostatin |
CN1324818A (zh) * | 2000-05-22 | 2001-12-05 | 烟台荣昌生物工程有限公司 | 生产内皮抑制素的方法 |
CN1661019A (zh) * | 2005-01-18 | 2005-08-31 | 南京大学 | 一种在大肠杆菌中生产重组内皮抑素的方法及其应用 |
CN1712413A (zh) * | 2004-06-14 | 2005-12-28 | 清华大学 | 组织纤维蛋白原的新用途 |
CN101224296A (zh) * | 2008-02-01 | 2008-07-23 | 山东先声麦得津生物制药有限公司 | 一种稳定的重组人血管内皮抑制素制剂及其制备工艺 |
-
2014
- 2014-07-03 CN CN201410315038.8A patent/CN105218660B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058498A1 (en) * | 1999-03-30 | 2000-10-05 | Merck & Co., Inc. | Soluble recombinant endostatin |
WO2001060839A2 (en) * | 2000-02-18 | 2001-08-23 | The United States Of America, As Represented By Secretary Of The Department Of Health And Human Services | Method for refolding recombinant endostatin |
CN1324818A (zh) * | 2000-05-22 | 2001-12-05 | 烟台荣昌生物工程有限公司 | 生产内皮抑制素的方法 |
CN1712413A (zh) * | 2004-06-14 | 2005-12-28 | 清华大学 | 组织纤维蛋白原的新用途 |
CN1661019A (zh) * | 2005-01-18 | 2005-08-31 | 南京大学 | 一种在大肠杆菌中生产重组内皮抑素的方法及其应用 |
CN101224296A (zh) * | 2008-02-01 | 2008-07-23 | 山东先声麦得津生物制药有限公司 | 一种稳定的重组人血管内皮抑制素制剂及其制备工艺 |
Non-Patent Citations (12)
Title |
---|
Angiogenesis—a new target for future therapy;Nilesh M. Pandya等;《Vascular Pharmacology》;20060531;第44卷(第5期);第265-274页 |
Endostatin Improves Radioresponse and Blocks Tumor Revascularization after Radiation Therapy for A431 Xenografts in Mice;Satoshi Itasaka等;《Int J Radiat Oncol Biol Phys.》;20070301;第67卷(第3期);第870-878页 |
Practical considerations in refolding proteins from inclusion bodies;Kouhei Tsumoto等;《Protein Expression and Purification》;20030331;第28卷(第1期);第1-8页 |
内皮抑素在大肠杆菌中表达、纯化及复性的研究;何晶晶等;《哈尔滨医科大学学报》;20061031;第40卷(第5期);第375-378页 |
内皮抑素联合放射治疗对A549细胞生长及HIF-1表达的影响;张彦彦等;《中国肺癌杂志》;20090131;第12卷(第1期);摘要 |
大肠杆菌表达的新一代重组人内皮抑素复性条件的优化;赵立希;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20101015(第10期);第36页第3.2-3.3节,第38-39页第5.2节 |
血管内皮抑素与顺铂对Calu-6肺癌细胞联合作用的观察;程鑫等;《天津医药》;20080901;第36卷(第5期);摘要 |
重组人内皮抑素层析复性的相关研究;乔路等;《华东理工大学学报(自然科学版)》;20080430;第34卷(第2期);第203-207页 |
重组人内皮抑素的纯化及抗肿瘤活性研究;张广美等;《中国肿瘤》;20050228;第14卷(第2期);第122-125页 |
重组人血管内皮抑制素联合化疗治疗117例晚期恶性肿瘤;刘梁等;《安徽医科大学学报》;20121031;第47卷(第10期);第1209-1211页 |
重组人血管内皮抑素联合同步放化疗治疗老年晚期非小细胞肺癌的临床观察;姜祖光等;《中国实用医刊》;20110930;第38卷(第18期);第55-58页 |
重组人血管抑素(rhAGN)包涵体变性与复性初探;田亚平等;《药物生物技术》;20050430;第12卷(第2期);第85-89页 |
Also Published As
Publication number | Publication date |
---|---|
CN105218660A (zh) | 2016-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6572212B2 (ja) | 治療用の改変霊長類l−メチオニナーゼ | |
CN101222940B (zh) | Rhcc在药物递送、过滤、化学催化及纳米颗粒生产中的用途 | |
CN104342444B (zh) | 一种重组trail蛋白及其制备方法和用途 | |
CN106632682A (zh) | 融合蛋白ifn-elp及其应用 | |
US11267853B2 (en) | Carbohydrate tethering at cell surfaces to induce immune response | |
US20210100916A1 (en) | Preparation and use of mitochondrion-targeting self-assembled protein nanoparticle | |
CN106715468A (zh) | 用于癌症靶向治疗的包含基于重组血红蛋白蛋白质或亚基的治疗剂的药物组合物 | |
CN103906760B (zh) | 用作抗原掩蔽剂的人乳铁蛋白衍生肽 | |
CN100537765C (zh) | 重组人血管抑素k1-3的制备工艺及其制品在肿瘤治疗药物中的应用 | |
CN107760661A (zh) | 药用激肽原酶的peg修饰物及其制备方法和应用 | |
CN102458478B (zh) | 白蛋白-淀粉样肽缀合物及其用途 | |
CN105218660B (zh) | 重组内皮抑素的新型纯化复性方法及其抗肿瘤应用 | |
CA2574124A1 (en) | Carrier for medicaments for obtaining oral bioavailability | |
JP2008308440A (ja) | 癌治療用薬剤送達ビヒクルおよびその製造方法ならびにそれを用いた製剤 | |
CN101185762A (zh) | 聚乙二醇类聚合物修饰的睫状神经营养因子及其制备方法 | |
CN102731658B (zh) | 一种Tat PTD-Endostatin重组蛋白及其制备方法与应用 | |
CN101781369A (zh) | 一种重组人精氨酸酶融合蛋白及其应用 | |
CN106749561B (zh) | 一种嗜麦芽窄食单胞菌外膜蛋白及其应用 | |
CN112641924B (zh) | 一种治疗甲状腺癌的药物及其制备方法和用途 | |
CN105985447B (zh) | 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
CN107216369A (zh) | 一种鱼精蛋白类似活性肽及其制备方法与应用 | |
CN103083681A (zh) | 一种治疗肿瘤的药物及其应用 | |
CN101381413A (zh) | 一种修饰的重组人内皮抑素及其应用 | |
CN101501069A (zh) | 蛋白质复合体及其制造方法 | |
CN101224297A (zh) | 重组人血管内皮抑制素在制药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200714 Address after: 215126 No. 277, green hill street, Suzhou Industrial Park, Jiangsu, Suzhou Patentee after: Suzhou Union Ark Biomedical Research and Development Co.,Ltd. Address before: 215126 No. 277, green hill street, Suzhou Industrial Park, Jiangsu, Suzhou Patentee before: BIOPHARMAGEN CORP., FANGZHOU SUZHOU |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 215126 Qingqiu Street 277, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee after: Suzhou Ark Pharmaceutical R&D Co.,Ltd. Country or region after: China Address before: 215126 Qingqiu Street 277, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee before: Suzhou Union Ark Biomedical Research and Development Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240218 Address after: No. 128 Jinling East Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215126 Patentee after: Suzhou Ark Biomedicine Co.,Ltd. Country or region after: China Address before: 215126 Qingqiu Street 277, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee before: Suzhou Ark Pharmaceutical R&D Co.,Ltd. Country or region before: China |